NASDAQ:SHPH Shuttle Pharmaceuticals Q3 2025 Earnings Report $0.49 +0.04 (+8.07%) Closing price 04:00 PM EasternExtended Trading$0.46 -0.03 (-5.52%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Shuttle Pharmaceuticals EPS ResultsActual EPS-$1.05Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AShuttle Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AShuttle Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Shuttle Pharmaceuticals Earnings HeadlinesShuttle Pharmaceuticals Holdings Inc SHPHMay 19, 2026 | morningstar.comMShuttle Pharmaceuticals Holdings, Inc.May 15, 2026 | edition.cnn.comNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 10 at 1:00 AM | Porter & Company (Ad)E.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin MinerMay 7, 2026 | globenewswire.comShuttle to Acquire United Dogecoin in Push to Build Public DOGE Mining PlatformMay 2, 2026 | finance.yahoo.comWhy is SHPH stock soaring today? Dogecoin mining pivot sparks rallyMay 2, 2026 | msn.comSee More Shuttle Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Shuttle Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shuttle Pharmaceuticals and other key companies, straight to your email. Email Address About Shuttle PharmaceuticalsShuttle Pharmaceuticals (NASDAQ:SHPH), a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.View Shuttle Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Chewy’s Growth Engine Is Stronger Than the Market ThinksEverpure: AI Storage Uncertainty Overshadows Breakneck GrowthIntel Is the Market's Most Mispriced AI HedgeUranium Energy Corp Melts Down—Nuclear Opportunity at HandShort Sellers Are Piling Into Wingstop, But Analysts See Big UpsideOptical Cable Corporation: Strong Earnings, But Hurdles RemainThe J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Upcoming Earnings Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
